The MOLL trial - Magnetic lesion localisation for breast cancer

Magnetic Occult Lesion Localization for the surgical management of non-palpable Breast Cancer: The MOLL trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN74635349

Enrollment

Registered

2017-09-20

Start date

2017-09-21

Completion date

Unknown

Last updated

2018-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Specialty: Cancer, Primary sub-specialty: Breast Cancer

Interventions

There is no randomisation or separate treatment arms, as all participants included in the study follow the same procedure. On the morning prior to surgery the participant receives an injection with a

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Males/females (18 years or over) 2. A non-palpable breast tumour 3. Visible on ultrasound 4. Suitable for wire guided lesion localisation;Inclusion criteria: 1. Males/females (18 years or over) 2. A non-palpable breast tumour 3. Visible on ultrasound 4. Suitable for wire guided lesion localisation

Exclusion criteria

Exclusion criteria: 1. Known intolerance / hypersensitivity to iron compounds 2. Patients with a pacemaker or other implantable devices in the chest wall;Exclusion criteria: 1. Known intolerance / hypersensitivity to iron compounds 2. Patients with a pacemaker or other implantable devices in the chest wall

Design outcomes

Primary

Measure	Time frame
Successful localization of a magnetic marker and excision of the breast tumour is assessed using a magnetic marker and magnetometer during surgery.;Successful localization of a magnetic marker and excision of the breast tumour is assessed using a magnetic marker and magnetometer during surgery.	—

Secondary

Measure	Time frame
1. Re-excision rate is assessed by reviewing patient notes post-operatively 2. Excised specimen volumes are assessed by weighting the excised tissue volumes during surgery 3. Cosmetic outcome is assessed by reviewing patient notes post-operatively after 3 months and at 1 year follow-up 4. Morbidity from WLE is assessed by reviewing patient notes post-operatively ;1. Re-excision rate is assessed by reviewing patient notes post-operatively 2. Excised specimen volumes are assessed by weighting the excised tissue volumes during surgery 3. Cosmetic outcome is assessed by reviewing patient notes post-operatively after 3 months and at 1 year follow-up 4. Morbidity from WLE is assessed by reviewing patient notes post-operatively	—

Measure

Time frame

1. Re-excision rate is assessed by reviewing patient notes post-operatively 2. Excised specimen volumes are assessed by weighting the excised tissue volumes during surgery 3. Cosmetic outcome is assessed by reviewing patient notes post-operatively after 3 months and at 1 year follow-up 4. Morbidity from WLE is assessed by reviewing patient notes post-operatively ;1. Re-excision rate is assessed by reviewing patient notes post-operatively 2. Excised specimen volumes are assessed by weighting the excised tissue volumes during surgery 3. Cosmetic outcome is assessed by reviewing patient notes post-operatively after 3 months and at 1 year follow-up 4. Morbidity from WLE is assessed by reviewing patient notes post-operatively

—

Countries

United Kingdom

Contacts

Public ContactMirjam;Mirjam Peek;Peek

;

mirjam.peek@gstt.nhs.uk;mirjam.peek@gstt.nhs.uk+44 2071880721;+44 2071880721

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026